This Friday, a group of vaccine and infectious disease experts will assemble virtually to discuss whether the Food and Drug Administration should clear Johnson & Johnson’s coronavirus vaccine for emergency use.
The meeting, convened by the FDA, is likely one of the last steps in the agency’s review of J&J’s shot. The regulator held similar meetings to review study results from Pfizer and Moderna and, each time, authorized the companies’ vaccines the very next day.